Agents for alleviating side effects

Abstract

The present invention provides an agent for alleviating side effects caused by use of an anti-tumor agent, which contains 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H-pyrimidi nedione (1) represented by formula (1): or a pharmaceutically acceptable salt thereof. The 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione or a pharmaceutically acceptable salt thereof exhibit an inflammatory-suppressing action in the digestive tract and advantageously alleviate diarrhea and loss of body weight concomitant with administration of a chemical for treating cancer without suppressing the anti-tumor effect. Thus, the compounds of the present invention are of great value as agents for alleviating side effects caused by use of an anti-tumor agent, which enable not only the chemotherapy to be continuedly carried out, but also the body exhaustion to be effectively prevented.

What is claimed is: 
     
       1. A method for alleviating side effects caused by use of an anti-tumor agent selected from the group consisting of an alkylating agent, a plant-derived compound, an antibiotic, or a platinum containing agent comprising administering 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione represented by formula (1): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof to a patient to whom an the anti-tumor agent has been administered. 
     
     
       2. A method according to  claim 1 , wherein the side effect caused by use of the anti-tumor agent is nausea, vomiting, diarrhea, anorexia, or loss of body weight. 
     
     
       3. A method according to  claim 1  or  2 , wherein the anti-tumor agent is an antimetabolite, an alkylating agent, a plant-derived compound, an antibiotic, or a platinum-containing agent. 
     
     
       4. A method according to  claim 1  or  2 , wherein the anti-tumor agent is 5-trifluoromethyl-2′-deoxyuridine, 5-fluorouracil, irinotecan hydrochloride, or cisplatin. 
     
     
       5. The method of claim 4, wherein the anti-tumor agent is irinotecan hydrochloride. 
     
     
       6. The method of claim 4, wherein the anti-tumor agent is cisplatin.